Daily Stock Analysis, GWPH, GW Pharmaceuticals PLC, priceseries

GW Pharmaceuticals PLC. Daily Stock Analysis
Stock Information
Open
150.00
Close
151.29
High
151.48
Low
148.51
Previous Close
150.22
Daily Price Gain
1.07
YTD High
152.19
YTD High Date
Feb 13, 2019
YTD Low
95.00
YTD Low Date
Jan 2, 2019
YTD Price Change
50.28
YTD Gain
49.78%
52 Week High
179.65
52 Week High Date
Sep 27, 2018
52 Week Low
90.14
52 Week Low Date
Dec 27, 2018
52 Week Price Change
20.62
52 Week Gain
15.78%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 3. 2017
118.68
Feb 22. 2017
126.68
12 Trading Days
6.74%
Link
LONG
Oct 31. 2017
107.95
Nov 29. 2017
120.26
20 Trading Days
11.40%
Link
LONG
Dec 13. 2017
123.98
Dec 29. 2017
133.34
11 Trading Days
7.55%
Link
LONG
Apr 9. 2018
114.33
Apr 30. 2018
133.45
15 Trading Days
16.72%
Link
LONG
May 1. 2018
135.17
Jun 7. 2018
156.97
26 Trading Days
16.13%
Link
LONG
Sep 18. 2018
149.20
Oct 2. 2018
160.96
10 Trading Days
7.88%
Link
LONG
Jan 4. 2019
108.88
Feb 7. 2019
139.61
23 Trading Days
28.22%
Link
Company Information
Stock Symbol
GWPH
Exchange
NasdaqGM
Company URL
http://www.gwpharm.com
Company Phone
44 1223 266800
CEO
Justin D. Gover
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001351288
About

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

Description

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the company's product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.